Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Details)

v3.6.0.2
Quarterly Financial Information (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 524 $ 635 $ 443 $ 3,962 $ 48,183 [1] $ 2,074 [1] $ 2,539 [1] $ 2,651 [1] $ 5,564 $ 55,447 $ 18,866
Restructuring costs (4,551)   21 (36) (1,138) (2,561)     4,566 3,699  
Operating costs and expenses (13,432) (12,727) (18,482) (17,915) (18,305) (23,191) (24,752) (25,224) (67,122) (95,171) (100,698)
Loss from operations (17,459) (12,092) (18,018) (13,989) 28,740 (23,678) (22,213) (22,573) (61,558) (39,724) (81,832)
Other income (expense), net [2] (21) (433) 2,858 5,624 (3,389) 23,198 (1,546) 855      
Net loss $ (17,480) $ (12,525) $ (15,160) $ (8,365) $ 25,351 $ (480) $ (23,759) $ (21,718) $ (53,530) $ (20,606) $ (38,301)
Basic net (loss) income per share of common stock $ (2.89) $ (2.10) $ (2.57) $ (1.45) $ 4.27 $ (0.08) $ (4.04) $ (3.74) $ (8.89) $ (3.50) $ (7.13)
Diluted net (loss) income per share of common stock $ (2.89) $ (2.10) $ (2.57) $ (1.45) $ 4.24 [3] $ (0.08) [3] $ (4.04) [3] $ (3.74) [3] $ (8.89) $ (3.50) $ (13.49)
[1] In the fourth quarter of 2015, total revenues include upfront and milestone payments relating to various out-licensing arrangements, including a $37.0 million upfront payment from Novartis, a $5.0 million upfront payment from Novo Nordisk and a $3.8 million payment from Pfizer.
[2] Fluctuations in 2016 and 2015 primarily relate to (losses) gains on the revaluation of the contingent warrant liabilities and a $3.5 million gain from the sale of the Company’s manufacturing facility during the three months ended December 31, 2015 (see Note 6).
[3] For the quarter ended December 31, 2015, the Company’s diluted net income per share of common stock was computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period.